ArticleCardiovascular diabetology2026
Tryptophan metabolites and stroke risk after acute myocardial infarction in patients with and without metabolic syndrome: insights from a MACCE-based cohort.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning and multi-omics technologies for precision cardiovascular medicine: advancing diagnosis, risk prediction, and therapeutic guidance.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMetabolic syndrome (MetS) obviously increases the risk of major adverse cardiac and cerebrovascular events (MACCE) in patients with acute myocardial infarction (AMI). However, the metabolic mechanisms underlying this heightened vulnerability remain unclear, and individualized predictive models are limited.
objectiveTo elucidate the role of tryptophan metabolism in MetS-related MACCE risk after AMI and to establish a machine learning model (random forest) for MACCE prediction.
methodsA total of 3223 AMI patients undergoing percutaneous coronary intervention were enrolled between 2017 and 2021. Through untargeted metabolomics analysis, potential MetS-related metabolites were screened and identified, followed by internal validation of tryptophan metabolites—indole-3-lactic acid (ILA), tryptophan (TRP), kynurenine (KYN), and indole-3-propionic acid (IPA)—in 3190 patients. Cox regression was performed separately for Mets and no-Mets participants to assess the associations of Tryptophan Levels and with a primary focus on stroke risk, and secondary analyses of other MACCE components. A random forest model was constructed to predict MACCE over a 72-month follow-up by integrating metabolic and clinical variables.
resultsPatients with MetS exhibited significant disturbances in tryptophan metabolism. Elevated levels of indole-3-lactic acid (ILA), tryptophan (TRP), and kynurenine (KYN) were independently associated with higher stroke risk in MetS patients (adjusted HR per twofold increase: ILA 1.34, TRP 1.46, KYN 1.47; all P < 0.05), but not in non-MetS individuals. The random forest model exhibited good prediction performance (AUC 0.715; 95% CI 0.683–0.747), identifying KYN, indole-3-lactic acid (ILA) as major predictive features.
conclusionTryptophan metabolic dysregulation, particularly elevated KYN, was associated with a higher risk of stroke in AMI-MetS patients. By integrating untargeted discovery, targeted validation, and machine learning–based modeling, our study provides a novel framework for individualized risk stratification and supports further investigation into the translational potential of metabolic biomarkers in this high-risk cardiometabolic population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.